☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Study 309 trial
Merck Presents Results of Keytruda (pembrolizumab) + Lenvima (lenvatinib) in P-III KEYNOTE-775/Study 309 trial for the Treatment o...
March 22, 2021
Load more...
Back to Home
Modal title
×
Modal body text goes here.